TORONTO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory ...

Alzheimer’s disease is the most common form of dementia, which is a general term for the loss of memory and intellectual abilities. Alzheimer’s disease is fatal and there is no cure. It is a ...

The funding agency aims to cap “indirect costs” in biomedical research grants. But this behind-the-scenes work is crucial to making research happen.

Determining the various costs of Medicare can be confusing. There are annual deductibles, monthly premiums and doctor visit ...

Corbus Pharmaceuticals has posted the first Western clinical data on its would-be rival to Pfizer’s Padcev. The overall ...

Corbus Pharmaceuticals presented new data from the first Western study of its antibody-drug conjugate treatment for cancer.

Health systems are facing hurdles to implementing new and effective metastatic urothelial carcinoma (mUC) therapies into ...

In the past two years, the Food and Drug Administration has approved two novel Alzheimer's therapies, based on data from clinical trials showing that both drugs slowed the progression of the disease.

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

Jubilant Biosys Innovative Research Services Pte. Limited, Singapore (JBIRSPL), a subsidiary of Jubilant Biosys Limited, a ...

In the past two years, the Food and Drug Administration has approved two novel Alzheimer's therapies, based on data from ...

Ersodetug, a novel, fully human monoclonal antibody for the treatment of hyperinsulinism (HI), receives Breakthrough Therapy Designation and ...